A5048300954- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Hemoglobinopathies and Related Disorders
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Blood groups and transfusion
- Viral-associated cancers and disorders
- Hematological disorders and diagnostics
- COVID-19 Clinical Research Studies
- Multiple Myeloma Research and Treatments
- Parvovirus B19 Infection Studies
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Cytomegalovirus and herpesvirus research
- Blood transfusion and management
- Respiratory viral infections research
- HER2/EGFR in Cancer Research
- T-cell and Retrovirus Studies
- Blood disorders and treatments
King Saud bin Abdulaziz University for Health Sciences
2017-2023
King Abdulaziz Medical City
2016-2023
King Abdullah International Medical Research Center
2017-2023
National Guard Health Affairs
2019-2023
Khalifa University of Science and Technology
2023
Sheikh Shakhbout Medical City
2023
Saudi Center for Organ Transplantation
2023
Mayo Clinic
2015-2020
Mayo Clinic Hospital
2020
McGill University
2005-2018
Summary Non‐myeloablative haematopoietic progenitor cell transplantation (HPCT) from matched related donors (MRD) has been increasingly utilized in sickle disease (SCD). A total of 122 patients received 300 cGy body irradiation (TBI), alemtuzumab, unmanipulated filgrastim‐mobilized peripheral blood HPC and sirolimus. The median follow‐up was four years; age at HPCT 29 years. Median neutrophil platelet engraftment occurred on day 22 19 respectively; 41 required no transfusions. Overall...
Screening for vancomycin-resistant Enterococcus (VRE) is performed at many transplant centers, but data on the impact of VRE colonization and bloodstream infection (BSI) hematopoietic cell transplantation (HCT) outcomes remain conflicting.Consecutive adults with acute myeloid leukemia who underwent allogeneic HCT between 2004 2014 were retrospectively reviewed. Patients screened by perirectal PCR swabs targeting vanA vanB twice weekly while inpatient.Of a total 203 patients (median age 54...
Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogenic hematopoietic cell transplantation (HCT). Corticosteroids are first-line treatment; however, less than one-half patients achieve durable remission. Studies suggest that TNF-α, a cytokine released from bone marrow during conditioning, involved in pathogenesis aGVHD. We retrospectively evaluated outcome anti-TNF-α therapy with infliximab 35 steroid refractory (SR) Infliximab was administered...
MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasm) overlap syndromes are myeloid malignancies for which allogeneic hematopoietic stem cell transplant (allo-HSCT) is potentially curative. We describe outcomes of 43 patients – 35 with chronic myelomonocytic leukemia, CMML (of 17 had blast transformation, BT) and eight MDS/MPN-unclassifiable (MDS/MPN,U). At median follow-up 21 months, overall survival (OS), cumulative incidence relapse (CIR) non-relapse mortality (NRM) were 55%,...
Limited data exist regarding the prevalence and outcome of medication nonadherence in adult allogeneic hematopoietic stem cell transplantation (allo-HSCT) population. The objective this cross-sectional survey study is to determine immunosuppressant nonimmunosuppressant medications recipients allo-HSCT. An electronic using previously validated adherence scales was distributed between December 2014 April 2015 200 patients with at least 3 months follow-up after Immunosuppressant serum drug...
Highlights•FB was associated with higher CIR and lower PFS compared FM in RIC-HCT.•Dose adjustment of busulfan based on AUC did not alter the risk relapse.•Engraftment acute or chronic GVHD rates were similar between both regimens.•FM an OS advantage patients KPS ≥ 90.AbstractFludarabine (FB) fludarabine melphalan (FM) are commonly used reduced-intensity conditioning (RIC) regimens. Pharmacokinetic dosing (Bu) is frequently done for myeloablative conditioning, but evidence its use limited...
Abstract There is a lack of large comparative study on the outcomes reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood Marrow Transplant Research who received first RIC allo-transplant between 2001 2015 were studied. Patients excluded if they cord blood or identical twin transplant, total body irradiation conditioning,...
The prognosis of acute myeloid leukemia (AML) remains poor. Among 180 patients, the median age was 53 (14-88) years. overall 2-year disease free survival (DFS) 28.6% (+/- 3.4), 47.7% 6.6%) for ≤ 40, 23.6% 5.8%) 41–60 and 11.7% 4.2%) ≥61 (p< 0.0001). (OS) 45.3% 3.8%), 78.6% 5.5%) ≤40, 43.5% 6.9%) 15.8% 4.8%) Induction outcome best in high dose chemotherapy (HDC) group (p < Only those ≤40 had durable DFS OS. HDC appears to improve older AML patients.
Respiratory syncytial virus (RSV) infection causes significant morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. Although ribavirin immunoglobulins are common components of therapy, the role adjunct corticosteroids is not established.We sought to evaluate corticosteroid utilization setting post-allo-SCT RSV our center assess post-transplant outcomes including pulmonary function decline.Patients with a history from 2008 2014 seen at institution were identified....
Introduction Hematological parameters are critical in disease diagnosis, management, and monitoring; however, complete blood count (CBC) reference intervals vary across populations. The aim of the current study was to provide ranges hematological parameters/indices healthy adult Saudi population. Methods A multicenter retrospective cross-sectional conducted with a sample employees who were screened pre-employment from January 2015 December 2019, at tertiary care hospitals three regions....
ABO incompatibility is not a contraindication to hematopoietic cell transplantation (HCT), but it has been associated with additional risks including delayed engraftment, pure red aplasia (PRCA), and higher transfusion needs. Data on these events patient survival after reduced-intensity conditioning (RIC) HCT are limited.A total of 127 consecutive patients, 86 acute myeloid leukemia 41 myelodysplastic syndromes, who underwent HLA-matched peripheral blood RIC allogenic between 2005 2014 were...
B-cell prolymphocytic leukemia (B-PLL) is a very rare tumor of monoclonal B-cells representing <1% all leukemias. The mean age at presentation 65–70 years with the disease frequently i...